Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(02): 182-189
DOI: 10.4103/ijmpo.ijmpo_73_16
Review Article

Immune Checkpoint Blockers and Ovarian Cancer

Chinmoy K Bose
Department of Gynaecological Oncology and Clinical Trial, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Although the idea, called “cancer immunotherapy,” is very appealing and has previously been shown to work in several mouse models of cancer, it has in general been very difficult to translate cancer immunotherapy approaches to humans. Because of this frustration, by the 1990s, many scientists and biotechnology companies had given up on the idea of cancer immunotherapy. After few years, first detection T-cell suppression of effect of cytotoxic T-lymphocyte antigen-4 (CTLA4) molecule was established. Antibody (Ab) to CTLA4 could increase T-cell starting a completely new age of tumor immunology. Immune checkpoints are new ways in manipulation of immunological control over malignant tumors. It has lent an important measure to manage, especially recurrent and refractory cancers and those cancer where there is an unmet need like recurrent melanoma, renal cell carcinoma, and recurrent ovarian cancer. As a new development, this subject is experiencing rapid progress, and multiple avenues are opening up. Although there are many hurdles to overcome this needs constant updating, especially for students of ovarian cancer who are looking at it with much hope.

Keywords

Immune checkpoint - ovarian cancer - T-cell


Publication History

Article published online:
06 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
  • 2 Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
  • 3 Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
  • 4 Richard C, Sunshine G, Benjamini E. Immunology: A Short Course. London: Wiley-Liss; 2003. p. 131.
  • 5 Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 2004;172:34-9.
  • 6 Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010;161:512-26.
  • 7 CDX-1127 – Monoclonal antibody targeting CD27. Celldex Therapeutics; Available from: http://www.celldex.com/pipeline/cdx-1127.php. [Last accessed on 2017 Apr 24].
  • 8 He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013;191:4174-83.
  • 9 Zimm A. Cancer Miracle Patients Studied Anew for Disease Clues; 12 April, 2014. Bloomberg. Available from: https://www.bloomberg.com/news/articles/2014-04-11/cancer-miracle-patients-studied-anew-for-disease-clues. [Last retrieved on 2015 Jun 25].
  • 10 Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecificimmuno-Oncology program at UBS Global Healthcare Conference. Pieris Pharmaceuticals; 19 May, 2015. Available from: http://www.pieris.com/news-and-events/press-releases/detail/500/pieris-pharmaceuticals-to-present-data-on-novel-anti-cd137. [Last retrieved on 2015 Jun 05].
  • 11 Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013;73:7189-98.
  • 12 Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013;1:320-31.
  • 13 Disrupting Tumor Evasion of the Immune System. Newlink Genetics. Available from: http://www.newlinkgenetics.com/platforms/ido-pathway-inhibitors/. [Last retrieved on 2015 Jun 05].
  • 14 Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015;27:39-46.
  • 15 Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008;14:28-36.
  • 16 Balkwill F, Mantovani A. Inflammation and cancer: Back to virchow? Lancet 2001;357:539-45.
  • 17 Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
  • 18 Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
  • 19 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
  • 20 Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
  • 21 Haskill S, Becker S, Fowler W, Walton L. Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer 1982;45:728-36.
  • 22 Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
  • 23 Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
  • 24 Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012;130:105-12.
  • 25 Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
  • 26 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
  • 27 Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
  • 28 Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. Ahigh M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 2014;7:19.
  • 29 Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875-80.
  • 30 Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013;19:1363-74.
  • 31 Liu Y, Zeng B, Zhang Z, Zhang Y, Yang R. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol 2008;129:471-81.
  • 32 Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
  • 33 Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-5.
  • 34 Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013;73:6900-12.
  • 35 Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy 2011;3:539-56.
  • 36 Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
  • 37 Doyle AM, Mullen AC, Villarino AV, Hutchins AS, High FA, Lee HW, et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med 2001;194:893-902.
  • 38 Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
  • 39 Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-7.
  • 40 Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005-10.
  • 41 Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, et al. Efficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. JClinOncol 2014;32 5 Suppl; abstr 5511). [Abstr #5511].
  • 42 Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. JClin Oncol 2015;33 (Suppl; abstr 5509). [Abstr #5510].
  • 43 Disis ML, Patel MR, Pant S, Infante JR, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. J ClinOncol 2015;33 (Suppl; abstr 5509). [Abstr #5509].
  • 44 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
  • 45 Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. Anew member of the immunoglobulin superfamily – CTLA-4. Nature 1987;328:267-70.
  • 46 Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65.
  • 47 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
  • 48 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
  • 49 Tarhini AA, Thalanayar PM. Melanoma adjuvant therapy. Hematol Oncol Clin North Am 2014;28:471-89.
  • 50 Clinical trial number NCT00527735. Phase II Study for Previously Untreated Subjects with Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC). Available from: http://www. ClinicalTrials.gov. [Last accessed on 2017 Apr 24].
  • 51 First-Line Gemcitabine, Cisplatin+Ipilimumab for Metastatic Urothelial Carcinoma Clinical trial number NCT01524991. Available from: http://www. ClinicalTrials.gov. [Last accessed on 2017 Apr 24].
  • 52 Clinical trial number NCT00323882. Phase I/II Study of MDX-010 in Patients with Metastatic Hormone-Refractory Prostate Cancer (MDX010-21) (COMPLETED. Available from: http://www. ClinicalTrials.gov. [Last accessed on 2017 Apr 24].
  • 53 Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_discontinuation_of_phase_iii_clinical_trial_for_patients_with_advanced_melanoma. [Last accessed on 2016 Apr 10].
  • 54 Mechanism of Pathway: CTLA-4 Inhibition. Available from: https://www.azimmuno-oncology.com/ctla-4-inhibition# Tremelimumab. [Last accessed on 2017 Apr 24].
  • 55 Poust J. Targeting metastatic melanoma. Am J Health Syst Pharm 2008;65 24 Suppl 9:S9-15.
  • 56 U.S. Food and Drug Administration. FDA Approves Keytruda for Advanced Melanoma; 04 September, 2014. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm465444.htm. [Last retrieved on 2015 Dec 24].
  • 57 Approves Anti-PD-1 Drug for Advanced Melanoma. Available from: http://www.cancernetwork.com/melanoma/fda-approves-pembrolizumab-keytruda-advanced-melanoma. [Last accessed on 2016 Apr 12].
  • 58 US 8952136 Antibodies to Human Programmed Death Receptor PD-1. Available from: http://www.google.co.in/patents/US8952136. [Last accessed on 2016 Apr 12].
  • 59 Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014;588:368-76.
  • 60 Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77.
  • 61 Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 2013;31:4199-206.
  • 62 Fairman D, Narwal R, Liang M, et al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2014;32 (suppl; abstr 2602). [Abstr 2602].
  • 63 Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li, X, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol 2014;32 (Suppl; abstr 8021^). [Abstr 8021].
  • 64 Merck-Pfizer Alliance. Merck-Pfizer Alliance Avelumab Fact Sheet. Available from: https://www.pfizer.com/files/news/asco/Merck-PfizerAlliance_AvelumabFactSheet_19May2015US.pdf. [Last retrieved on 2015 Dec 02].
  • 65 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
  • 66 Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.
  • 67 Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009;114:2667-77.
  • 68 Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010;16:1042-8.
  • 69 Hodi FS, Lee SJ, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (IPI) versus IPI alone in metastatic melanoma: E1608. J Clin Oncol 2013;31 (Suppl; abstr CRA9007). [Abstr CRA9007].
  • 70 Antonia SJ, Gettinger SN, Chow LQ, Juergens RA, Borghae H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol 2014;32 (Suppl; abstr 8023). [Abstr 8023].
  • 71 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.